We provide you with 20 years of free, institutional-grade data for EDIT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of EDIT. Explore the full financial landscape of EDIT stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-12 | 1650664 | EDIT | 10-Q | Url |
| 2025-05-12 | 1650664 | EDIT | 10-Q | Url |
| 2025-03-05 | 1650664 | EDIT | 10-K | Url |
| 2024-11-04 | 1650664 | EDIT | 10-Q | Url |
| 2024-08-07 | 1650664 | EDIT | 10-Q | Url |
| 2024-05-08 | 1650664 | EDIT | 10-Q | Url |
| 2024-02-28 | 1650664 | EDIT | 10-K | Url |
| 2023-11-03 | 1650664 | EDIT | 10-Q | Url |
| 2023-08-02 | 1650664 | EDIT | 10-Q | Url |
| 2023-05-05 | 1650664 | EDIT | 10-Q | Url |
| 2023-02-22 | 1650664 | EDIT | 10-K | Url |
| 2022-11-02 | 1650664 | EDIT | 10-Q | Url |
| 2022-08-03 | 1650664 | EDIT | 10-Q | Url |
| 2022-05-04 | 1650664 | EDIT | 10-Q | Url |
| 2022-02-24 | 1650664 | EDIT | 10-K | Url |
| 2021-11-09 | 1650664 | EDIT | 10-Q | Url |
| 2021-08-05 | 1650664 | EDIT | 10-Q | Url |
| 2021-05-06 | 1650664 | EDIT | 10-Q | Url |
| 2021-02-26 | 1650664 | EDIT | 10-K | Url |
| 2020-11-06 | 1650664 | EDIT | 10-Q | Url |
| 2020-08-07 | 1650664 | EDIT | 10-Q | Url |
| 2020-05-08 | 1650664 | EDIT | 10-Q | Url |
| 2020-02-26 | 1650664 | EDIT | 10-K | Url |
| 2019-11-12 | 1650664 | EDIT | 10-Q | Url |
| 2019-08-07 | 1650664 | EDIT | 10-Q | Url |
| 2019-05-08 | 1650664 | EDIT | 10-Q | Url |
| 2019-03-01 | 1650664 | EDIT | 10-K | Url |
| 2018-11-08 | 1650664 | EDIT | 10-Q | Url |
| 2018-08-07 | 1650664 | EDIT | 10-Q | Url |
| 2018-05-04 | 1650664 | EDIT | 10-Q | Url |
| 2018-03-08 | 1650664 | EDIT | 10-K | Url |
| 2017-11-08 | 1650664 | EDIT | 10-Q | Url |
| 2017-08-09 | 1650664 | EDIT | 10-Q | Url |
| 2017-05-15 | 1650664 | EDIT | 10-Q | Url |
| 2017-03-03 | 1650664 | EDIT | 10-K | Url |
| 2016-11-09 | 1650664 | EDIT | 10-Q | Url |
| 2016-08-10 | 1650664 | EDIT | 10-Q | Url |
| 2016-05-13 | 1650664 | EDIT | 10-Q | Url |
| 2016-03-30 | 1650664 | EDIT | 10-K | Url |
| 2016-01-04 | 1650664 | EDIT | S-1 | Url |
Editas Medicine, Inc(NASDAQ:EDIT) 
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. ...
Website: http://www.editasmedicine.com
Founded: 2013
Full Time Employees: 208
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about EDIT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.